Anavex Life Sciences recently announced promising results from a 48-week
Phase 2 extension study involving their lead drug candidate, ANAVEX®2-73, aimed
at treating Parkinson’s disease dementia. The biopharmaceutical company, known
for its focus on neurodegenerative and neurodevelopmental disorders, reported
that the study met both its primary and secondary objectives, showing
significant clinical benefits. 

The study, ANAVEX2-73-PDD-EP-001, assessed various efficacy endpoints including cognitive
and motor functions. Patients treated with ANAVEX®2-73 demonstrated
improvements across all measured parameters. Particularly, the Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores, a
key measure of Parkinson’s disease progression, indicated notable positive changes. 

Anavex Life Sciences plans to move forward with a pivotal trial based on these results.
Dr. Christopher U Missling, President and CEO of Anavex, highlighted the
potential of ANAVEX®2-73 to not only slow but potentially reverse the
debilitating symptoms of Parkinson’s disease. He noted that the consistent
improvement in patients’ clinical symptoms during the extension phase is encouraging. 

The study also included a ‘drug holiday’ period due to delays caused by the COVID-19 pandemic.
This period allowed researchers to observe the effects of discontinuing and
then resuming ANAVEX®2-73 treatment. The data showed a worsening of symptoms
during the drug holiday and significant improvement upon resumption, further
emphasizing the drug’s efficacy. 

Anavex Life Sciences has received support from the Michael J. Fox Foundation for
Parkinson’s Research, which awarded a research grant for this study. This
aligns with Anavex’s mission to develop novel therapeutics for CNS disorders, including Parkinson’s
disease, Alzheimer’s disease, and Rett syndrome. 

The company’s continued efforts in the field of neurodegenerative diseases mark a significant
step forward in addressing these challenging conditions. For more information,
visit Anavex Life Sciences at www.anavex.com. 

Read this article for more information. 

More about Anavex on https://www.marketwatch.com/investing/stock/avxl